The Oxford University / AstraZeneca COVID-19 vaccine dose will be issued out of the box on January 2, 2021 at the Princess Royal Hospital, Haywards Heath, West Sussex, UK.
Gareth Fuller | Reuters
Drug user AstraZeneca is trying to adjust its Covid-19 vaccine in the face of new variants of the virus, with the process becoming more urgent after a small study found it was less effective at protecting against the more virulent strain discovered in South Africa.
The country said it would stop using the shot in its vaccination program According to a study published on Sunday that has not yet been peer-reviewed, the vaccine was found to offer “minimal protection” against mild to moderate illnesses caused by the South African variant.
Researchers from the University of Witwatersrand and others in South Africa, as well as the University of Oxford, found the study was small with only about 2,000 volunteers, with a mean age of 31 years. Oxford University said: “Protection from moderate to severe illness, hospitalization or death could not be assessed in this study because the target group was exposed to such a low risk.”
Vaccine manufacturers had already started developing second-generation Covid vaccines that are designed to target new variants of the virus. Experts say tweaking existing vaccines to cover mutations shouldn’t be too difficult, and they could be adjusted within six weeks.
Sarah Gilbert, professor of vaccination science at Oxford University who developed the vaccine with AstraZeneca, said Sunday that “efforts are being made to develop a new generation of vaccines that will allow protection on new variants as booster jabs redirect if it does, it turns out to be necessary to do so. “
“We are working with AstraZeneca to optimize the pipeline that would be required for a strain change should one become necessary. This is the same problem that all vaccine developers face and we will continue to monitor the emergence of new variants that arise in the readiness for a future change of burden. “
The variant, officially known as the B.1.351 mutation, was first detected in South Africa in October 2020 and has since become dominant in the country.
Several cases have also been found elsewhere where health officials have made efforts to stop the spread of the mutation, which has been found to be more contagious. There were already concerns that this variant might be more resistant to coronavirus vaccines developed last year.
With the use of the AstraZeneca-Oxford University Jab stopped, the South African government will instead offer vaccines made by Johnson & Johnson and Pfizer.
Johnson & Johnson reported in late January that his single-dose shot was 57% effective in one of his clinical studies in South Africa, in which almost all cases of Covid-19 (95%) were due to infection with the variant from the B.1.351 line. For comparison, the vaccine was found to be 72% effective in the US arm of the study.
Pfizer-BioNTech and Moderna both reported early indications that their vaccinations provide protection against new known variants of the virusfound in South Africa and the UK
On Friday, Oxford University released details of a separate study showing the vaccine was effective against a variant of the virus that was first discovered in south-east England and has now become the dominant strain in the UK
Andrew Pollard, professor of pediatric infections and immunity and lead investigator for the Oxford vaccine study, said data from studies of its vaccine in the UK “shows that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1 .7 which caused the disease surge across the UK from late 2020. “